The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Phase IIb , randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
Abstract
Aim: This Phase IIb , randomized, double‐blind, placebo‐controlled trial evaluated the efficacy, safety, tolerability and pharmacokinetics of empagliflozin in patients with type 2 diabetes. Methods: Four hundred and eight patients (treatment‐naïve or after a 4‐week wash‐out period) were randomized to receive empagliflozin 5, 10 or 25 mg once daily, placebo or open‐label metformin for 12 weeks. The primary endpoint was change in haemoglobin A1c ( HbA1c ) after 12 weeks. Results: After 12 weeks' treatment, empagliflozin showed dose‐dependent reductions in HbA1c from baseline [5 mg: −0.4%, 10 mg: −0.5%, 25 mg: −0.6%; all doses p < 0.0001 vs. placebo (+0.09%)]. Fasting plasma glucose ( FPG ) decreased with empagliflozin [5 mg: −1.29 mmol/l, 10 mg: −1.61 mmol/l, 25 mg: −1.72 mmol/l; all doses p < 0.0001 vs. placebo (+0.04 mmol/l)]. Body weight decreased in all empagliflozin groups (all doses p < 0.001 vs. placebo). The incidence of adverse events ( AEs ) was similar in the placebo (32.9%) and empagliflozin (29.1%) groups. The most frequently reported AEs on empagliflozin were pollakiuria (3.3% vs. 0% for placebo), thirst (3.3% vs. 0% for placebo) and nasopharyngitis (2.0% vs. 1.2% for placebo). AEs consistent with urinary tract infections ( UTIs ) were reported in four (1.6%) patients on empagliflozin vs. one (1.2%) on placebo. Genital infections were reported in five (2%) patients on empagliflozin vs. 0% on placebo. No UTIs or genital infections led to premature discontinuation. Conclusions: In patients with type 2 diabetes, empagliflozin resulted in dose‐dependent, clinically meaningful reductions in HbA1c and FPG , and reductions in body weight compared with placebo. Empagliflozin was well‐tolerated with a favourable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
List, J. F., & Whaley, J. M. (2011) · Kidney International · doi:10.1038/ki.2010.512 · Cited by 184 · cited 1×
“This could be due to adaptation of endogenous glucose output to the drop in plasma glucose and insulin levels [3] and to the extent of urinary glucose excretion being partly dependent on plasma glucose levels [16].”
Background
Cited by
Sodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Self-citationScheen, A. J. (2015) · Drugs · doi:10.1007/s40265-014-0337-y · Cited by 554
Lavalle-González, F. J., Januszewicz, A., Davidson, J., Tong, C., Qiu, R., Canovatchel, W., & Meininger, G. (2013) · Diabetologia · doi:10.1007/s00125-013-3039-1 · Cited by 492
Vallon, V., Gerasimova, M., Rose, M. A., Masuda, T., Satriano, J., Mayoux, E., Koepsell, H., Thomson, S. C., & Rieg, T. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00520.2013 · Cited by 483
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 450
Self-citationChino, Y., Samukawa, Y., Sakai, S., Nakai, Y., Yamaguchi, J., Nakanishi, T., & Tamai, I. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1909 · Cited by 389
Kovacs, C. S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA‐REG PIO™ trial investigators (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12188 · Cited by 387
Self-citationRidderstråle, M., Andersen, K. R., Zeller, C., Kim, G., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70120-2 · Cited by 378
Self-citationEmpagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA-REG METSU Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2673 · Cited by 371
Self-citationMazidi, M., Rezaie, P., Gao, H., & Kengne, A. P. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.116.004007 · Cited by 347
“Data were sorted by first author, year of publication, country of the study, design, age range of the participants, total sample size, SGLT2 inhibitor, comparator, number of patients, dosage, and follow-up duration (Table 1).(13-55)”
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
Nauck, M. (2014) · Drug Design, Development and Therapy · doi:10.2147/dddt.s50773 · Cited by 343
SGLT inhibitors in management of diabetes
Tahrani, A. A., Barnett, A. H., & Bailey, C. J. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70050-0 · Cited by 332
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
Wilding, J. P. H., Charpentier, G., Hollander, P., González‐Gálvez, G., Mathieu, C., Vercruysse, F., Usiskin, K., Law, G., Black, S., Canovatchel, W., et al. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12322 · Cited by 317
Oelze, M., Kröller-Schön, S., Welschof, P., Jansen, T., Hausding, M., Mikhed, Y., Stamm, P., Mader, M., Zinßius, E., Agdauletova, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112394 · Cited by 293
Monami, M., Nardini, C., & Mannucci, E. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12244 · Cited by 284
Han, J. H., Oh, T. J., Lee, G., Maeng, H. J., Lee, D. H., Kim, K. M., Choi, S. H., Jang, H. C., Lee, H. S., Park, K. S., et al. (2017) · Diabetologia · doi:10.1007/s00125-016-4158-2 · Cited by 281
Genital and urinary tract infections in diabetes: Impact of pharmacologically-induced glucosuria
Geerlings, S., Fonseca, V., Castro-Diaz, D., List, J., & Parikh, S. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.12.052 · Cited by 274
SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1
Novikov, A., Fu, Y., Huang, W., Freeman, B., Patel, R., van Ginkel, C., Koepsell, H., Busslinger, M., Onishi, A., Nespoux, J., et al. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00462.2018 · Cited by 186
“One unexplained phenomenon relates to the well-documented serum uric acid level-lowering effect of SGLT2 inhibitors (2, 7, 12, 24).”
BackgroundCai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
Xu, L., & Ota, T. (2017) · Adipocyte · doi:10.1080/21623945.2017.1413516 · Cited by 134
Seidu, S., Kunutsor, S. K., Cos, X., Gillani, S., & Khunti, K. (2018) · Primary Care Diabetes · doi:10.1016/j.pcd.2018.02.001 · Cited by 82
Yasui, A., Lee, G., Hirase, T., Kaneko, T., Kaspers, S., von Eynatten, M., & Okamura, T. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0385-5 · Cited by 75
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“[18] In head-to-head trials versus other glucose-lowering agents, empagliflozin showed a similarly low risk of hypoglycemia compared with metformin [56,57] and sitagliptin [57,59,60], but a much lower risk than glimepiride.”
BackgroundMethodInfluentialCai, X., Gao, X., Yang, W., Chen, Y., Zhang, S., Zhou, L., Han, X., & Ji, L. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12760 · Cited by 64
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
Sotagliflozin as a potential treatment for type 2 diabetes mellitus
Cariou, B., & Charbonnel, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1100361 · Cited by 37
The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors
Cangoz, S., Chang, Y.-Y., Chempakaseril, S. J., Guduru, R. C., Huynh, L. M., John, J. S., John, S. T., Joseph, M. E., Judge, R., Kimmey, R., et al. (2013) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12077 · Cited by 35
Bloomgarden, Z. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12065 · Cited by 13
Metadata
- Authors
- Ferrannini, E., Seman, L., Seewaldt‐Becker, E., Hantel, S., Pinnetti, S., & Woerle, H. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2013-03-04
- Volume
- 15
- Issue
- 8
- Pages
- 721-728
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2137107263
- Cited by
- 181
- References
- 2
- FWCI
- 25.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.